Skip to main content

Advertisement

Table 1 Neutralizing antibody titers of rhesus monkeys selected as SHIVIG donors

From: Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose

RM Homologous clade C viruses Heterologous clade C viruses Heterologous clade B viruses
SHIV-1157ip (early, tier 1) SHIV-1157ipd3N4 (late, tier 2) HIVZM135M HIV1084i HIVpIndieC HIVZM233M.PB6 HIVZM109F SHIV-2873Nip SHIVSF162P3 HIVSF162.LS HIVNL4-3 SHIV89.6P
RAo-8 2,048 >640 <20   128 42 <20 >640 <40 220 32  
RCt-10 360 >640       >640   6,500   
RHo-10 250 >640       >640     
RHy-9 600 >10,240 <20 100 90 <20 <20 >640   173   100
RJa-9 1,800 >10,240 <20   128 59 22 2,048 68 35,770 128  
RLu-9 >1,280 >640 <20 50 47 <20 <20 >640   58   75
RMf-9 2,048 >640 <20   128 <20 35 >640 78 18,303 128  
RPo-10 200 >640       >640     
RTs-7 2,048 >640    128    >640    32  
  1. NAb titers (reciprocal dilution of sera giving 50% reduction in virus replication) were determined in TZM-bl cells or, for SHIV-1157ipd3N4 and SHIV-2873Nip, in human PBMC-based assays. The SHIVs were prepared in RM PBMC; HIV1084i, HIVNL4-3 and HIVpIndieC were prepared in human PBMC; nAb titers against the remaining HIV strains were performed using pseudoviruses generated in transfected 293 T cells. All neutralization assays were performed at least in duplicate.